Suven Life Sciences Bags 2 Patents From India And Japan, Shares Rise
With these two additions, Suven now has 19 patents in India and Japan each.
Suven Life Sciences Ltd. rose after the company bagged two patents from India and Japan for products used for the treatment of certain disorders related to neurodegenerative diseases such as Alzheimer’s disease, ADHD, Huntington’s disease and Parkinson.
The Indian patent is valid through 2016 while the Japanese patent is valid through 2033, the company said in a filing on the Bombay Stock Exchange.
Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I (first stage of human testing) or Phase-II (group testing).Suven Life Sciences press release
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in
CNS arena that are being developed for cognitive disorders with high unmet medical need with
huge market potential globally”, said Venkat Jasti, chief executive officer of Suven Life Sciences in the release.
With these two additions, Suven now has 19 patents in India and Japan each.
Shares of the drug maker rose as much as 3.6 percent to Rs 195 post announcement.